- Completed the Halneuron® Phase 2b trial in Chemotherapy Induced Neuropathy, top-line results to be announced in November 2026 - - Phase 2b Long-Term Extension Study fully recruited, 95 patients enrolled, assessing
- Largest Shareholder Increases Position as Dogwood Advances Halneuron® Toward Topline Phase 2b Data Readout in November 2026 - - Expected Proceeds from the Investment Enable Acceleration of Phase 3 Preparatory
ATLANTA, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (NASDAQ:DWTX) (the "Company"), a company that focuses on developing first-in-class, new non-opioid medicines to treat pain and neuropathy,
- Enrollment of 239 Patients Meets Upper End of Planned Enrollment Target Range - - Topline Data Expected in November 2026 - ATLANTA, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (NASDAQ:DWTX)
ALPHARETTA, Ga., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (NASDAQ:DWTX) ("Dogwood" or the "Company"), a company that focuses on developing first-in-class, new non-opioid medicines
- Halneuron® Phase 2b trial in Chemotherapy Induced Neuropathy on track for top-line results in fall 2026, 217 patients enrolled – - Commencement of Phase 2b Long-Term Extension Study to assess Halneuron® reduction in
ATLANTA, July 20, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (NASDAQ:DWTX) (the "Company"), a development-stage biotechnology company developing new medicines to treat pain and neuropathy, today
ALPHARETTA, Ga., June 30, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (NASDAQ:DWTX) ("Dogwood" or the "Company"), a company that focuses on developing first-in-class, new non-opioid medicines
New study to assess Halneuron® pain reduction effect over three months of treatment, additional safety data to bolster planned end of Phase 2 FDA submission package Patients completing the ongoing Halneuron®
- Halneuron® Phase 2b trial in Chemotherapy Induced Neuropathy on track for top-line results in fall 2026 - - FDA acceptance of SP16 Investigational New Drug Application for the treatment of Chemotherapy Induced
ATLANTA, May 07, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (NASDAQ:DWTX) ("Dogwood" or the "Company"), a company that focuses on developing new medicines to treat pain and neuropathy, today announced that it
- PRIDCor Therapeutics Granted Global Development and Commercialization License for IMC-1 and IMC-2 Assets for All Indications, including Fibromyalgia and Long-COVID - - Dogwood Granted a Tiered Royalty up to 15% on Net
Dogwood licensed SP16 to treat cancer-related pain from partner and regulatory sponsor Serpin Pharma The SP16 Phase 1b trial fully funded by the National Cancer Institute; Patient enrollment expected to commence in the
ATLANTA, March 18, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (NASDAQ:DWTX) (the "Company"), a development-stage biotechnology company developing new medicines to treat pain and neuropathy, today announced
- Low early termination rate (4.3%) among the first 116 patients completing the study suggests Halneuron® treatment to be well tolerated - ATLANTA, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc.
